Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Stock Has Consensus Target Price of $3.17 According to Analysts

Key Points

• Analysts maintain a Moderate Buy consensus on Inovio Pharmaceuticals, with five buy ratings, one strong buy, one hold and one sell. The average 12-month price target is $3.17, well above the reported share price of $1.21.
• Institutional ownership stands at 26.79%, with several hedge funds recently initiating or increasing positions, including Caitong International Asset Management, which expanded its stake substantially.
• Inovio reported quarterly EPS of -$0.07, beating the consensus estimate of -$0.22. The biotechnology company develops DNA-based medicines for cancer, infectious diseases and HPV-related conditions.

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $3.17.

A number of research analysts have weighed in on the stock. Weiss Ratings lowered shares of Inovio Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, August 13th. Jefferies Financial Group upgraded Inovio Pharmaceuticals from a "hold" rating to a "positive" rating and upped their price target for the company from $1.80 to $3.00 in a research report on Thursday, August 13th. Zacks Research upgraded Inovio Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 12th. Wall Street Zen raised Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Finally, Piper Sandler restated an "overweight" rating and issued a $4.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Eversept Partners LP purchased a new position in Inovio Pharmaceuticals during the first quarter worth about $1,802,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Inovio Pharmaceuticals by 1,929.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 48,948 shares of the biopharmaceutical company's stock valued at $85,000 after buying an additional 46,536 shares during the period. Engineers Gate Manager LP acquired a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $37,000. Squarepoint Ops LLC increased its holdings in shares of Inovio Pharmaceuticals by 46.5% during the 2nd quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 11,554 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at approximately $33,000. Hedge funds and other institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Stock Down 0.8%

Inovio Pharmaceuticals stock opened at $1.21 on Friday. The company has a fifty day simple moving average of $1.11 and a 200-day simple moving average of $1.19. The firm has a market capitalization of $125.11 million, a price-to-earnings ratio of -1.33 and a beta of 1.61. Inovio Pharmaceuticals has a 52-week low of $0.56 and a 52-week high of $2.72.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. On average, research analysts anticipate that Inovio Pharmaceuticals will post -0.72 EPS for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines designed to treat and prevent serious diseases. Its platform uses synthetic DNA plasmids to instruct cells to produce targeted proteins, with delivery supported by its CELLECTRA electroporation devices. The company's research has included candidates for cancer, infectious diseases and human papillomavirus (HPV)-related conditions.

Inovio's pipeline has included INO-3107, an investigational DNA immunotherapy for recurrent respiratory papillomatosis, a rare disease caused by HPV, as well as other development programs targeting cancers and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.